TLSI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLSI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TriSalus Life Sciences's Enterprise Value is $133.22 Mil. TriSalus Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-44.98 Mil. Therefore, TriSalus Life Sciences's EV-to-FCF for today is -2.96.
The historical rank and industry rank for TriSalus Life Sciences's EV-to-FCF or its related term are showing as below:
During the past 3 years, the highest EV-to-FCF of TriSalus Life Sciences was -0.67. The lowest was -15.81. And the median was -2.77.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-13), TriSalus Life Sciences's stock price is $3.91. TriSalus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.490. Therefore, TriSalus Life Sciences's PE Ratio (TTM) for today is At Loss.
The historical data trend for TriSalus Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
EV-to-FCF | - | - | -4.16 |
TriSalus Life Sciences Quarterly Data | |||||||||||
Dec21 | Mar22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | -2.76 | -4.16 | -5.02 | -2.80 | -3.39 |
For the Medical Devices subindustry, TriSalus Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's EV-to-FCF falls into.
TriSalus Life Sciences's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 133.220 | / | -44.98 | |
= | -2.96 |
TriSalus Life Sciences's current Enterprise Value is $133.22 Mil.
TriSalus Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (NAS:TLSI) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TriSalus Life Sciences's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 3.91 | / | -2.490 | |
= | At Loss |
TriSalus Life Sciences's share price for today is $3.91.
TriSalus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of TriSalus Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Mats Wahlstrom | director, 10 percent owner | 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401 |
Mary T Szela | director, officer: CEO and President | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
George Kelly Martin | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Jodi Devlin | officer: President, Therapeutics | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
James Alecxih | officer: President, Device Technology | C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065 |
Bryan F. Cox | officer: Chief Scientific & Manufact. | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Kerry R Hicks | director | C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228 |
Jennifer Stevens | officer: Chief Regulatory Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Richard Marshak | officer: Sr.VP, Corp. Dev. & Strategy | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Anil K. Singhal | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Sean Murphy | director, officer: Chief Financial Officer | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
Arjun Jj Desai | director | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Steven C Katz | officer: Chief Medical Officer | C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031 |
Von Eschenbach Andrew C. | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Equity Ab Frankenius | 10 percent owner | BOX 984, BORAS V7 SE-501 10 |
From GuruFocus
By Business Wire • 07-01-2024
By Business Wire • 08-10-2023
By Business Wire • 03-07-2024
By Business Wire • 08-15-2024
By Business Wire • 03-26-2024
By Business Wire • 11-07-2023
By Business Wire • 10-14-2024
By GuruFocus News • 11-13-2024
By Business Wire • 04-30-2024
By Business Wire • 05-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.